Evidence map›Paper›PMID 28983907›Full record

ArticleBritish journal of pharmacology2017

Rapid vasodilation to raloxifene: role of oestrogen receptors and off-target effects.

Matthias Barton, Eric R Prossnitz

Abstract readLetterComment
PubMed Full text at PMC Publisher
In one paragraph

Article in British journal of pharmacology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors.

Matthias BartonMolecular Internal Medicine, University of Zurich, Zürich, Switzerland.
Eric R ProssnitzDivision of Molecular Medicine, Department of Internal Medicine, and University of New Mexico Comprehensive Cancer Center, University of New Mexico Health Sciences Center, Albuquerque, NM, USA.ORCID 0000-0001-9190-8302

Funding

Molecular Mechanisms and Applications of Novel ER/GPER-selective LigandsR01CA194496 · NCI · UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR · PI ARTERBURN, JEFFREY B, PROSSNITZ, ERIC R · 2016 to 2025
$4.1M
G protein-coupled estrogen receptor GPER and breast carcinogenesisR01CA163890 · NCI · UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR · PI PROSSNITZ, ERIC R · 2012 to 2023
$3.3M
Development of GPR30-Selective LigandsR01CA127731 · NCI · UNIVERSITY OF NEW MEXICO · PI ARTERBURN, JEFFREY B, OPREA, TUDOR I · 2008 to 2012
$1.7M
NCI NIH HHS R01 CA127731NCI NIH HHS R01 CA163890NCI NIH HHS R01 CA194496
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Raloxifene HydrochlorideReceptors, EstrogenAnimalsAortaEndotheliumNitric Oxide Synthase Type IIRatsSelective Estrogen Receptor ModulatorsVasodilationNitric Oxide Synthase Type IIRaloxifene HydrochlorideReceptors, EstrogenSelective Estrogen Receptor Modulators

Identifiers

PMID28983907
PMCPMC5660003

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.